↓ Skip to main content

BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease

Overview of attention for article published in Alzheimer's Research & Therapy, December 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news
1 news outlet
blogs
1 blog
twitter
5 X users
patent
5 patents
facebook
1 Facebook page

Citations

dimensions_citation
337 Dimensions

Readers on

mendeley
481 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
Published in
Alzheimer's Research & Therapy, December 2014
DOI 10.1186/s13195-014-0089-7
Pubmed ID
Authors

Robert Vassar

Abstract

β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is the β-secretase enzyme required for the production of the neurotoxic β-amyloid (Aβ) peptide that is widely considered to have a crucial early role in the etiology of Alzheimer's disease (AD). As a result, BACE1 has emerged as a prime drug target for reducing the levels of Aβ in the AD brain, and the development of BACE1 inhibitors as therapeutic agents is being vigorously pursued. It has proven difficult for the pharmaceutical industry to design BACE1 inhibitor drugs that pass the blood-brain barrier, however this challenge has recently been met and BACE1 inhibitors are now in human clinical trials to test for safety and efficacy in AD patients and individuals with pre-symptomatic AD. Initial results suggest that some of these BACE1 inhibitor drugs are well tolerated, although others have dropped out because of toxicity and it is still too early to know whether any will be effective for the prevention or treatment of AD. Additionally, based on newly identified BACE1 substrates and phenotypes of mice that lack BACE1, concerns have emerged about potential mechanism-based side effects of BACE1 inhibitor drugs with chronic administration. It is hoped that a therapeutic window can be achieved that balances safety and efficacy. This review summarizes the current state of progress in the development of BACE1 inhibitor drugs and the evaluation of their therapeutic potential for AD.

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 481 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 4 <1%
United Kingdom 1 <1%
Belgium 1 <1%
China 1 <1%
Denmark 1 <1%
Japan 1 <1%
Russia 1 <1%
Unknown 471 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 110 23%
Student > Ph. D. Student 71 15%
Student > Master 69 14%
Researcher 57 12%
Other 20 4%
Other 59 12%
Unknown 95 20%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 78 16%
Agricultural and Biological Sciences 63 13%
Pharmacology, Toxicology and Pharmaceutical Science 55 11%
Neuroscience 52 11%
Chemistry 47 10%
Other 69 14%
Unknown 117 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 24. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 August 2018.
All research outputs
#1,333,941
of 22,780,967 outputs
Outputs from Alzheimer's Research & Therapy
#186
of 1,212 outputs
Outputs of similar age
#19,607
of 353,039 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#2
of 17 outputs
Altmetric has tracked 22,780,967 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,212 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 24.2. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,039 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.